Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish
  • Turkish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Microbiota transplant and type 1 diabetes mellitus: a trial in humans
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Microbiota transplant and type 1 diabetes mellitus: a trial in humans
Gastroenterology

Microbiota transplant and type 1 diabetes mellitus: a trial in humans

Metabolic syndrome
Gastroenterology Endocrinology

Fecal microbiota transplantation is accompanied by changes in microbial metabolites and T cells involved in autoimmunity and may preserve residual function of pancreatic β-cells in type 1 diabetes mellitus.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 08 February 2021
Updated 29 March 2022

Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of pancreatic β-cells. Studies in mice suggest that interactions between the gut microbiota and the innate immune system are involved in the development of the disease, the progression of which may be slowed by fecal microbiota transplantation (FMT).

Autologous versus allogenic transplantation

In a randomized controlled trial, patients recently diagnosed with T1DM received three FMTs by nasoduodenal tube at 0, 2 and 4 months, either from their own feces (autologous FMT, n=10) or from the feces of healthy donors (allogenic FMT, n=10). In the year following the first FMT, the researchers evaluated residual β-cell function (via C-peptide release in response to a test meal), as well as metabolic, immune and microbiota changes induced by the two types of FMT.

Pancreatic function preserved

Contrary to the researchers’ expectations, β-cell function was preserved in the autologous group one year after the first FMT. β-cell function deteriorated in the allogenic group, however, although less than in (sidenote: Overgaard AJ, Weir JM, Jayawardana K, et al. Plasma lipid species at type 1 diabetes onset predict residual beta-cell function after 6 months. Metabolomics 2018;14:158; Lachin JM, McGee PL, Greenbaum CJ, et al. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS One 2011;6:e26471 ) . According to the researchers, the benefits of FMT may be more pronounced and long-lasting where immunological compatibility between donor and host is high.

Desulfovibrio piger involved?

Changes in the microbiota were found to be associated with certain metabolic and immune changes. In the duodenum, the presence of Prevotella spp. was inversely correlated with residual β-cell function. In the colon, Desulfovibrio piger became significantly more abundant following autologous FMT only. Its abundance was associated with improved residual β-cell function and increased levels of plasma 1-arachidonoyl-GPC (A-GPC), a microbial metabolite associated with increased C-peptide production. In addition, the abundance of D. piger was negatively correlated with levels of certain T cells involved in autoimmunity. What was the significance according to the authors? D. piger may inhibit autoimmunity by suppressing these T cells via the production of A-GPC. From the multiple correlations found, the researchers have identified mechanistic leads that will need to be further investigated to clarify the effects of FMT on T1DM. They have also newly identified the therapeutic potential of certain bacterial species.

Sources

de Groot P, Nikolic T, Pellegrini S et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut. 2021 Jan;70(1):92-105.

Tags
Transplantation Diabetes FMT Pancreas Fecal transplants

en_view en_sources

    Created 08 February 2021
    Updated 29 March 2022

    About this article

    To know more about this topic.

    Main topic

    Metabolic syndrome

    Medical practice

    Gastroenterology Endocrinology

    Content type

    News
    Gastroenterology

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Microbiota in covid-19 pandemic

    Overview By Pr. Conceição Calhau NOVA Medical School, New University of Lisbon, Portugal By Pr. Pedro Povo...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Continue reading

    News
    22.11.2021

    Irritable bowel syndrome: is fecal microbiota transplantation effective in the long term?

    Read the article
    Cancer du pancréas : un diagnostic précoce non invasif grâce au microbiote fécal ?
    16.06.2022

    Pancreatic cancer: non-invasive early diagnosis thanks to the fecal microbiota?

    Read the article
    Photo: Régime méditerranéen « vert » : quels liens entre santé cardiométabolique et microbiote intestinal ?
    10.06.2022

    Green Mediterranean diet: what links between cardiometabolic health and gut microbiota?

    Read the article
    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria
    02.06.2022

    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria

    Read the article
    18.05.2022

    Gut microbiota and vitamin D: a promising team in the fight against osteoporosis?

    Read the article
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish
    • Turkish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Postménopause : l'action bénéfique de l'estradiol sur le microbiote vaginal
    22.06.2022

    Postmenopause: the beneficial action of estradiol on the vaginal microbiota

    Read the article
    WMD_Foundation KOL USA 2018
    17.06.2022

    Dr. Yang (USA winner 2018): Gut microbiota & gut brain axis

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo